ReviewClinical drug investigation2024

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.

Edurne Arriola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.